



Stanley F. Chavire

Member

Direct 781-697-2268

Fax 781-622-5933

Waltham, MA

schavire@morse.law

Dr. Stanley F. Chavire is a Registered Patent Attorney, specializing in patent prosecution, licensing of intellectual property, and related counseling. Stan advises clients in developing and implementing strategies to protect their intellectual property, with a particular focus on clients in the life sciences industry.

Stan counsels clients with respect to the preparation and prosecution of utility patents and design patents, the evaluation of intellectual property portfolios, and regulatory exclusivity matters. Stan also supports clients' domestic and international licensing initiatives by conducting in-depth due diligence evaluations and by negotiating and drafting a variety of license, development, and supply agreements.

Prior to beginning his legal career Stan practiced as a Registered Pharmacist in both clinical and retail settings, advising physicians and patients with regard to the optimization of drug therapies, the identification and resolution of drug-drug and drug-disease state interactions, and performing drug utilization reviews.

Representative Matters

- Represented **Oscient Pharmaceuticals Corporation** in its \$78 million purchase of the U.S. rights to the cardiovascular drug Antara (fenofibrate) from Reliant Pharmaceuticals.
- Represented **Oscient Pharmaceuticals Corporation** in its acquisition of worldwide rights to Ramoplanin from Pfizer Inc. subsidiary Vicuron Pharmaceuticals Inc.
- Represented **Agrivida, Inc.** in its research alliance with Syngenta Ventures to develop advanced crop technology and provide Agrivida access to Syngenta crop technology and intellectual property.
- Represented **ETEX Corporation** in its sale to Zimmer Holdings, Inc.

Education

Suffolk University Law School, J.D.

Massachusetts College of Pharmacy and Health Sciences, B.S., Pharm.D.

Admissions

Massachusetts Bar

U.S. Patent & Trademark Office

Practice Areas

Corporate

Intellectual Property

Licensing & Commercial Contracts

Patent

Industries

Educational Institutions & Hospitals

Life Sciences

Medical Devices

Software-as-a-Service

Recognition

2024 Go To Lawyer for Health Care & Life Science
– *Massachusetts Lawyers Weekly*



MA Rising Stars
2014 – 2015



Sandoz Inc. v. Amgen Inc.: Supreme Court Clarifies BPCIA Provisions

Supreme Court Denies Sequenom's Petition to Clarify Scope of Mayo in *Sequenom v. Ariosa*

Global Medical Device Regulatory Strategy

A Tangled Web of Post-Patent Expiry Royalty Obligations

United States Completes Hague Agreement Deposit For Industrial Designs

Massachusetts Enacts Biosimilar Substitution Law

FDA Revises Interpretation of 5-year NCE Exclusivity